What is EpiBiologics?
EpiBiologics is pioneering a next-generation protein degradation platform designed to target extracellular membrane and soluble proteins. Founded on research from Dr. Jim Wells at the University of California, San Francisco (UCSF), the company's proprietary EpiTAC platform utilizes a modular bispecific antibody system. This innovative approach enables tissue-specific degradation of disease-driving extracellular proteins, positioning EpiBiologics to develop first-in-class and best-in-class targeted therapies. The company's strategic focus spans multiple therapeutic areas, including oncology and immunology, aiming to address significant unmet patient needs.
How much funding has EpiBiologics raised?
EpiBiologics has raised a total of $157M across 2 funding rounds:
Series A
$50M
Series B
$107M
Series A (2023): $50M with participation from Google Ventures, Vivo Capital, Mubadala GE Capital PJSC, and Polaris Partners
Series B (2026): $107M led by Novartis Venture Fund, GV, Johnson & Johnson Services Inc, Samsara BioCapital, and Polaris Partners
Key Investors in EpiBiologics
Novartis Venture Fund
The Novartis Venture Fund invests in innovative life science companies focused on biotechnology and biopharmaceutical therapeutics that address unmet patient needs. With over USD 750 million in committed capital, the fund supports a diverse portfolio of more than 40 companies across North America and Europe.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors. The company focuses on enterprise solutions, life sciences, consumer products, and frontier technology innovations.
Johnson & Johnson Services Inc
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies. It provides innovative medicines, surgical products, and medical devices used in areas such as oncology, immunology, neuroscience, and cardiovascular care.
What's next for EpiBiologics?
With substantial capital infusion, EpiBiologics is poised for significant expansion and advancement of its therapeutic programs. The recent major strategic investment, following earlier rounds of financing, indicates a strong market validation for its protein degradation technology. This backing will likely fuel further research and development, clinical trial progression, and potential expansion into new therapeutic indications. The company's trajectory suggests a move towards scaling its operations and solidifying its position as a leader in targeted protein degradation therapies.
See full EpiBiologics company page
